Ribociclib (Kisqali®) added to the PBS


Ribociclib (Kisqali®) added to the PBS

More than 3000 breast cancer patients will get access to cheaper medication after the cost of a life changing drug was slashed over the weekend.

The federal government has listed ribociclib (brand name Kisqali ®) on the Pharmaceutical Benefits Scheme (PBS) which when used in combination with other treatments, slows the progression of inoperable or metastatic breast cancers in patients.

Previously the medication had cost breast cancer sufferers more than $70,000 a year, but now patients will be able to access the drug for between $39.50 and $6.40 per script.

For more information on this announcement you can watch Chanel Ten’s news report or read more on the Sunday Mail Adelaide website.


Image courtesy of Novartis.